SkylineDx Announces That CP-GEP (Merlin CP-GEP) is Now Recognized by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) as a Predictive GEP Test That May be Used in Select Cutaneous Melanoma Patients to Assess Metastatic Risk<\/span><\/strong><\/a><\/h2><\/div>Learn More<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Empowering Personalized Melanoma Care with the Merlin\u2122 Test<\/h1><\/div><\/div><\/div><\/div><\/div>![](\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271040%27%20height%3D%2728%27%20viewBox%3D%270%200%201040%2028%27%3E%3Crect%20width%3D%271040%27%20height%3D%2728%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" "\\"3-4")
<\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>![](\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27388%27%20height%3D%27225%27%20viewBox%3D%270%200%20388%20225%27%3E%3Crect%20width%3D%27388%27%20height%3D%27225%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" "\\"new-merlin-logo-large\\"")
<\/span><\/div><\/div>Crucial tumor insight for personalized melanoma care<\/strong><\/h2><\/div>Co-developed by SkylineDx and the Mayo Clinic, the Merlin Test is the only non-invasive genomic test for primary cutaneous melanomas that combines clinicopathologic variables (CP) and gene expression profiling (GEP) into a single algorithm (CP-GEP).<\/p>\n<\/div>
<\/div>![](\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%277719%27%20height%3D%271550%27%20viewBox%3D%270%200%207719%201550%27%3E%3Crect%20width%3D%277719%27%20height%3D%271550%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" "\\"Test-Flowchart-Graphic-new-logo\\"")
<\/span><\/div><\/div>The Merlin\u2122<\/sup> Test Provides:<\/strong><\/h3><\/div>\u2022 An actionable binary result: Low Risk<\/span><\/strong> or High Risk<\/span><\/strong>
\n\u2022 Patient\u2019s risk of nodal metastasis
\n\u2022 5-10 year survival outcome<\/p>\n<\/div><\/div><\/div><\/div><\/div>Integrate your medical expertise with the Merlin Test.<\/strong><\/h2><\/div><\/div><\/div>Collaborating with leading melanoma experts worldwide, at SkylineDx we are committed to addressing the complex challenges of challenges associated with all stages of cutaneous melanomas.<\/p>\n
Genomic testing plays an important role in the decision-making process, offering unique insights into the biology of an individual\u2019s tumor and supporting more personalized treatment strategies.<\/p>\n
The Merlin Test provides timely results that guide cutaneous melanoma management including surgical interventions and treatment.<\/p>\n
The Merlin Test is covered by Medicare and we have financial support programs in place to assist patients with out-of-pocket expenses.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
Empowering Personalized Melanoma Care with the Merlin\u2122 Test<\/h1><\/div><\/div><\/div><\/div><\/div><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/span><\/div><\/div>Crucial tumor insight for personalized melanoma care<\/strong><\/h2><\/div>Co-developed by SkylineDx and the Mayo Clinic, the Merlin Test is the only non-invasive genomic test for primary cutaneous melanomas that combines clinicopathologic variables (CP) and gene expression profiling (GEP) into a single algorithm (CP-GEP).<\/p>\n<\/div>
<\/div><\/span><\/div><\/div>The Merlin\u2122<\/sup> Test Provides:<\/strong><\/h3><\/div>\u2022 An actionable binary result: Low Risk<\/span><\/strong> or High Risk<\/span><\/strong>
\n\u2022 Patient\u2019s risk of nodal metastasis
\n\u2022 5-10 year survival outcome<\/p>\n<\/div><\/div><\/div><\/div><\/div>Integrate your medical expertise with the Merlin Test.<\/strong><\/h2><\/div><\/div><\/div>Collaborating with leading melanoma experts worldwide, at SkylineDx we are committed to addressing the complex challenges of challenges associated with all stages of cutaneous melanomas.<\/p>\n
Genomic testing plays an important role in the decision-making process, offering unique insights into the biology of an individual\u2019s tumor and supporting more personalized treatment strategies.<\/p>\n
The Merlin Test provides timely results that guide cutaneous melanoma management including surgical interventions and treatment.<\/p>\n
The Merlin Test is covered by Medicare and we have financial support programs in place to assist patients with out-of-pocket expenses.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
![](\"https:\/\/merlinmelanomatest.com\/us\/wp-content\/uploads\/2021\/06\/3-4-BAR.svg\" "\\"3-4")
<\/span><\/div><\/div><\/div>![](\"https:\/\/merlinmelanomatest.com\/us\/wp-content\/uploads\/sites\/2\/2026\/03\/new-merlin-logo-large.svg\" "\\"new-merlin-logo-large\\""){kind=logo}
<\/span><\/div>Crucial tumor insight for personalized melanoma care<\/strong><\/h2><\/div>Co-developed by SkylineDx and the Mayo Clinic, the Merlin Test is the only non-invasive genomic test for primary cutaneous melanomas that combines clinicopathologic variables (CP) and gene expression profiling (GEP) into a single algorithm (CP-GEP).<\/p>\n<\/div>
<\/div><\/span><\/div><\/div>The Merlin\u2122<\/sup> Test Provides:<\/strong><\/h3><\/div>\u2022 An actionable binary result: Low Risk<\/span><\/strong> or High Risk<\/span><\/strong>
\n\u2022 Patient\u2019s risk of nodal metastasis
\n\u2022 5-10 year survival outcome<\/p>\n<\/div><\/div><\/div><\/div><\/div>Integrate your medical expertise with the Merlin Test.<\/strong><\/h2><\/div><\/div><\/div>Collaborating with leading melanoma experts worldwide, at SkylineDx we are committed to addressing the complex challenges of challenges associated with all stages of cutaneous melanomas.<\/p>\n
Genomic testing plays an important role in the decision-making process, offering unique insights into the biology of an individual\u2019s tumor and supporting more personalized treatment strategies.<\/p>\n
The Merlin Test provides timely results that guide cutaneous melanoma management including surgical interventions and treatment.<\/p>\n
The Merlin Test is covered by Medicare and we have financial support programs in place to assist patients with out-of-pocket expenses.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
Co-developed by SkylineDx and the Mayo Clinic, the Merlin Test is the only non-invasive genomic test for primary cutaneous melanomas that combines clinicopathologic variables (CP) and gene expression profiling (GEP) into a single algorithm (CP-GEP).<\/p>\n<\/div>
![](\"https:\/\/merlinmelanomatest.com\/us\/wp-content\/uploads\/sites\/2\/2026\/03\/Test-Flowchart-Graphic-new-logo.svg\" "\\"Test-Flowchart-Graphic-new-logo\\""){kind=logo}
<\/span><\/div>The Merlin\u2122<\/sup> Test Provides:<\/strong><\/h3><\/div>\u2022 An actionable binary result: Low Risk<\/span><\/strong> or High Risk<\/span><\/strong>
\n\u2022 Patient\u2019s risk of nodal metastasis
\n\u2022 5-10 year survival outcome<\/p>\n<\/div><\/div><\/div><\/div><\/div>Integrate your medical expertise with the Merlin Test.<\/strong><\/h2><\/div><\/div><\/div>Collaborating with leading melanoma experts worldwide, at SkylineDx we are committed to addressing the complex challenges of challenges associated with all stages of cutaneous melanomas.<\/p>\n
Genomic testing plays an important role in the decision-making process, offering unique insights into the biology of an individual\u2019s tumor and supporting more personalized treatment strategies.<\/p>\n
The Merlin Test provides timely results that guide cutaneous melanoma management including surgical interventions and treatment.<\/p>\n
The Merlin Test is covered by Medicare and we have financial support programs in place to assist patients with out-of-pocket expenses.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
\u2022 An actionable binary result: Low Risk<\/span><\/strong> or High Risk<\/span><\/strong> Collaborating with leading melanoma experts worldwide, at SkylineDx we are committed to addressing the complex challenges of challenges associated with all stages of cutaneous melanomas.<\/p>\n Genomic testing plays an important role in the decision-making process, offering unique insights into the biology of an individual\u2019s tumor and supporting more personalized treatment strategies.<\/p>\n The Merlin Test provides timely results that guide cutaneous melanoma management including surgical interventions and treatment.<\/p>\n The Merlin Test is covered by Medicare and we have financial support programs in place to assist patients with out-of-pocket expenses.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
\n\u2022 Patient\u2019s risk of nodal metastasis
\n\u2022 5-10 year survival outcome<\/p>\n<\/div><\/div><\/div><\/div><\/div>Integrate your medical expertise with the Merlin Test.<\/strong><\/h2><\/div><\/div><\/div>
![](\"https:\/\/merlinmelanomatest.com\/us\/wp-content\/uploads\/2021\/06\/play-button.svg\")
<\/a>